+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy



Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy



Cardiovascular Revascularization Medicine 15(3): 131-136



The comparative prognostic value of low density lipoprotein-cholesterol (LDL-C) and C-reactive protein (CRP) in patients with stable coronary artery disease (CAD) treated with percutaneous coronary intervention (PCI) and statin therapy is poorly investigated. The study included 7595 patients with stable CAD treated with PCI. Based on a cut-off of 100mg/dl for LDL-C and 3mg/L for CRP, patients were divided into 4 groups: patients with LDL-C≤100mg/dl and CRP≤3mg/L (n=2795); patients with LDL-C>100mg/dl and CRP≤3mg/L (n=2091); patients with LDL-C≤100mg/dl and CRP>3mg/L (n=1296); and patients with LDL-C>100mg/dl and CRP>3mg/L (n=1413). Statins at discharge were prescribed in all patients. The primary outcome was 1-year all-cause mortality. One-year mortality was 2.1% (160 deaths): 1.2% (33 deaths) among patients with LDL-C ≤100mg/dl and CRP≤3mg/L, 1.4% (28 deaths) among patients with LDL-C>100mg/dl and CRP≤3mg/L, 4.8% (60 deaths) among patients with LDL-C≤100mg/dl and CRP>3mg/L and 2.9% (39 deaths) among patients with LDL-C>100mg/dl and CRP>3mg/L (P<0.001). After adjustment, CRP (hazard ratio [HR]=1.64, 95% confidence interval [CI] 1.33-2.02, for 1 standard deviation increase in the logarithmic scale) but not LDL-C (HR=1.03 [0.90-1.17], for 30mg/dl increase) showed an independent association with 1-year mortality. CRP (P=0.045) but not LDL-C (P=0.294) increased the discriminatory power of multivariable model for prediction of mortality. In patients with stable CAD treated with PCI and statin therapy, CRP but not LDL-C was independently associated with increased risk of 1-year mortality.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052215721

Download citation: RISBibTeXText

PMID: 24630704

DOI: 10.1016/j.carrev.2014.02.003


Related references

Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention. American Journal of Cardiology 116(7): 999-1002, 2015

Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis 24(11): 1125-1131, 2017

Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology 2019, 2019

Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. European Journal of Internal Medicine 24(2): 145-150, 2013

Percutaneous coronary intervention causes prolonged c-reactive protein increase in patients with stable coronary artery disease. Atherosclerosis 235(2): E138-E139, 2014

Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial). American Journal of Cardiology 112(11): 1703-1708, 2014

Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease. Coronary Artery Disease 20(4): 288-294, 2009

Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 224(2): 454-456, 2013

Elevated high sensitivity C-reactive protein after percutaneous coronary intervention in patients with stable coronary artery disease; a proof-of-concept study. Atherosclerosis Supplements 33: e2-e3, 2018

High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography. European Journal of Clinical Investigation 38(6): 372-380, 2008

Evaluation of oxidized low-density lipoprotein in the coronary circulation of patients with coronary artery disease, and its association with percutaneous coronary intervention. International Journal of Cardiology 134(3): E117-E119, 2008

High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. International Heart Journal 59(2): 300-306, 2018

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. American Journal of Cardiology 104(12): 1647-1653, 2010

Optimal medical therapy with or without percutaneous coronary intervention for stable coronary artery disease is effective in patients with chronic kidney disease. 2007

C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. American Heart Journal 158(2): 277-283, 2009